While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...
Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its EVOKE-01 study, revealed for the first time at this year’s ASCO.
The vaccine primes the immune system to attack the tumour cells, while Keytruda blocks an immunological ... the administration of the personalised shot is upwards of eight weeks, and efforts ...
Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...
Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...
IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.
In front of a sold-out hometown crowd at Scope Arena in Norfolk, Virginia, and with his brothers fighting on the undercard ...
The corporate regulator ASIC is doing a deep dive into the superannuation industry to probe whether funds are paying out death and disability claims on time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback